

**REMARKS**

The Office Action mailed October 20, 2003, has been received and reviewed. Claims 1, 4, 5, 8, 9, 11, 12, 15, 21, 23, 72, 74, 75 and 78 are pending. Claim 23 has been canceled without prejudice or disclaimer. Claims 74 and 75 stand objected to for formalities. Claim 23 stands rejected under 35 U.S.C. § 112, first and second paragraph. Claim 21 stands rejected under 35 U.S.C. § 112, second paragraph, as assertedly being indefinite. Claims 1, 4, 5, 8, 9, 11, 12, 15, 21, 23, 72, 74, 75 and 78 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking enablement commensurate with the scope of the claims. Reconsideration is respectfully requested.

Interview:

The applicants wish to thank the Examiner for the courtesy of the telephonic interview conducted on December 17, 2003. As discussed in the interview, the applicants have amended the claims to overcome the claim objections and to more clearly recite the bioassay of claim 1.

Support for claim amendments:

Support for amended claim 1 can be found throughout the specification, for example, at page 10, line 16 to page 12, line 2. Support for amended claim 74 can be found can be found throughout the specification, for example, at page 1, line 22 to page 2, line 4. Support for amended claim 75 can be found can be found throughout the specification, for example, at pending claim 15.

Objections to the Specification:

The specification was objected to for assertedly failing to comply with the suggested arrangement of the specification. The applicants herewith submit a substitute specification, which conforms the arrangement of the specification to the arrangement suggested by the Office. In accordance with 37 C.F.R. § 1.125 a clean copy and a marked up version showing all of the changes made to the specification are provided as Appendix A and B, respectively. The present

**Appl. No. 09/202,104**  
**Amdt. dated January 20, 2004**  
**Reply to Office Action of October 20, 2003**

specification includes the amendments submitted on July 15, 2003 (Abstract and Cross-Reference to Related Applications), and July 30, 2002 (Brief Description of Figures), which are not shown as changes made to the specification. The applicants respectfully submit that the substitute specification contains no new matter.

Objections directed to Claims 74 and 75:

Claim 74 stands objected to for reasons relating to syntax in the preamble. The Office suggests that the phrase "exerting agonistic IL-6 activity" could be amended to recite "inducing proliferation of B9 cells" (page 2 of Paper 22). The applicants respectfully submit that the syntax of the preamble is correct as written and that amending the preamble to recite the specific example used to demonstrate an agonistic IL-6 activity would not improve the syntax of the claim. Specifically, the preamble, including the syntax of the preamble, reasonably apprises those skilled in the art both of the utility (exerting agonistic IL-6 activity) and scope of the invention (MPEP § 2173.05(a)). Thus, reconsideration and withdrawal of the objection is respectfully requested.

Claim 75 stands objected to because a mixture comprises more than one item. Applicants have amended claim 75 to recite "an inert carrier," thereby adding a second element to the "mixture." Reconsideration and withdrawal of the objection is thus respectfully requested.

Rejections directed to Claim 23:

Claim 23 stands rejected under 35 U.S.C. § 112, first and second paragraph. Claim 23 has been canceled, thereby mooting the rejections.

Rejection of Claim 21:

Claim 21 stands rejected under 35 U.S.C. § 112, second paragraph, as assertedly being indefinite, as it is allegedly unclear what the intent is of culturing cells in the presence of the claimed compounds. The applicants respectfully submit that the claim is not indefinite for the asserted lack of intent for culturing cells in the presence of the claimed compound. "If the

**Appl. No. 09/202,104**  
**Amdt. dated January 20, 2004**  
**Reply to Office Action of October 20, 2003**

claims, read in light of the specification, reasonably apprise those skilled in the art both of the utilization and scope of the invention, and if the language is as precise as the subject matter permits, the statute (35 U.S.C. § 112, second paragraph) demands no more" (MPEP § 2173.05(a).

The specification specifically expresses the utility of culturing cells in the presence of the claimed compounds. For example, culturing cells in the presence of a relatively low concentration of the peptides (*e.g.*, about 7.5 to about 120 µg/ml) may be used to enhance cell growth and higher concentrations (*e.g.*,  $\geq 120$  µg/ml) may be used to decrease cell growth (*see*, for example, page 15, lines 29-37 of the specification). Thus, the applicants submit that the claim, when read in light of the specification, clearly indicates the utility of culturing cells in the presence of the compounds of claim 1 (page 4 of Paper 22). Further, because the output of culturing cells in the presence of the claimed compounds can have opposing effects, agonistic or antagonistic, depending on the concentration of the compound used, the language is as precise as the subject matter permits. Reconsideration and withdrawal of the rejection is respectfully requested.

Rejection of claims 1, 4, 5, 8, 9, 11, 12, 15, 21, 23, 72, 74, 75 and 78 under 35 U.S.C. § 112, first paragraph:

Claims 1, 4, 5, 8, 9, 11, 12, 15, 21, 23, 72, 74, 75 and 78 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly lacking enablement commensurate with the scope of the claims. Specifically, the Office asserts that the specification does not reasonably provide enablement for all agonist and antagonistic assays (page 3 of Paper 22). While the applicants respectfully disagree that the specification is not enabling for all agonist and antagonistic assays, to expedite prosecution of the application, claim 1 has been amended to recite "said bioassay comprising contacting IL-6-dependent cells with said isolated, recombinant or purified peptide and determining an effect of said isolated, recombinant or purified peptide on IL-6 stimulation of said IL-6-dependent cells." Thus, the assay is now expressly set forth in the claims, as amended. As a result, the amount of experimentation required to practice the full scope of the claim is minimal and clearly does not rise to the level of undue experimentation. Reconsideration and withdrawal

**Appl. No. 09/202,104**  
**Amdt. dated January 20, 2004**  
**Reply to Office Action of October 20, 2003**

of the rejections are respectfully requested.

**Conclusion**

In view of the foregoing amendments and remarks, applicants respectfully submit that the claims are in condition for allowance. If any questions remain after consideration of the foregoing, the Office is kindly requested to contact applicants' attorney at the address or telephone number given herein.

Respectfully submitted,



G. Scott Dorland, Ph.D.  
Registration No. 51,622  
Attorney for Applicants  
TRASKBRITT, P.C.  
P.O. Box 2550  
Salt Lake City, Utah 84110-2550  
Telephone: 801-532-1922

Date: January 20, 2004  
GSD/gsd

# **APPENDIX B**

**(VERSION OF SUBSTITUTE SPECIFICATION EXCLUDING CLAIMS  
WITH MARKINGS TO SHOW CHANGES MADE)**

**(Serial No.: 09/202,104)**

## IL-6 AND IL-6-RECEPTOR DERIVED PEPTIDES HAVING IL-6 ANTAGONISTIC OR AGONISTIC ACTIVITY

### CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation of PCT/NL97/00345, filed June 19, 1997, designating the United States of America, corresponding to PCT International Publication WO 97/48728 (published in English on December 24, 1997).

### BACKGROUND

[0002] Technical Field: The invention relates to the field of cytokines.

[0003] Cytokines are substances that are produced by cells of the immune system and are involved in regulation of humoral and cellular immune reactions and inflammatory responses. Many cytokines are known, and all exert influence on various reactions in the body in a complicated fashion. To illustrate their interdependency and the intricate web of relationships that exist between cytokines, one often speaks about the "cytokine network".

[0004] Interleukine 6 (IL-6) is a cytokine which has many effects upon mammalian cells. It exerts these effects through binding to a specific cell surface receptor, that consists of a specific  $\alpha$ -subunit of with a molecular weight of approximately 80 kD and a common  $\beta$ -subunit of approximately 130 kD, also named gp130. The gp130  $\beta$  chain is also involved in signal transduction of interleukin-11. (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1) (P.B. Sehgal, Ling Wang, Ravi Rayanade et al., pp 1-14; volume 762, Annals of the New York Academy of Sciences; 1995).

[0005] IL-6 is an extremely pleiotropic cytokine, and its activities include: induction of Ig production by B cells, stimulation of B and T cell growth, differentiation of T cells and macrophages, induction of acute phase protein production by hepatocytes, multilineage hematopoiesis, osteoclast formation, maturation of megakaryocytes, and platelet production. IL-6 also effects the central nervous system: IL-6 is an endogenous pyrogen and can induce ACTH production by the pituitary, finally resulting in increased glucocorticoid levels in the circulation. IL-6 exerts its activity by triggering a transmembrane receptor that is present on all target cells. Specific steps in the IL-6 signaling cascade are the binding to the low affinity  $\alpha$ -chain (CD126).

The complex of IL-6 and  $\alpha$ -chain binds with the high affinity signal transducing  $\beta$ -chain (GP130, CD130).

[0006] In healthy individuals no or only very low levels of IL-6 (<10 pg/ml) are detectable in the circulation. IL-6 levels are increased in various diseases, and it is postulated that these increased levels play a causative role in the pathogenesis of these diseases. Examples of diseases where increased levels of IL-6 are found are multiple myeloma, AIDS lymphoma, polyclonal B cell activation as observed in AIDS, rheumatoid arthritis, cardiac myxoma and Castleman's disease, mesangial proliferative glomerulonephritis, psoriasis, cancer-associated cachexia, postmenopausal osteoporosis, sepsis, multiple system organ failure, alcohol cirrhosis, and diseases of the central nervous system like Alzheimer, among others. Evidence for the causative role of IL-6 in the pathogenesis of some of the above-mentioned diseases has come from phase I/II clinical trials with IL-6 neutralizing monoclonal antibodies. Treatment with anti-IL-6 monoclonal antibodies reversed fever, acute phase proteins, night sweats, bone destruction, and cachexia. Treatment of a patient with Castleman disease with anti-IL-6 monoclonal antibodies reduced acute phase protein levels, fever, anemia, thrombocytosis, and hypergamma-globulinemia. Improvement of patients was also observed in patients with rheumatoid arthritis. Apparently, reduction of IL-6 activity in these patients resulted in improvement of the clinical signs of their disease.

[0007] This approach for treating disease by antagonizing IL-6 activity makes use of monoclonal antibodies directed to IL-6. However, monoclonal antibodies are usually not of human origin and repeated administration of non-human monoclonal antibodies generally leads to immune responses against the constant part of the antibodies, since this is foreign to the body of the patient. This immune reaction to the monoclonal antibodies used in the treatment is, first of all, counterproductive to the therapeutic treatment itself. The monoclonal antibodies used will be rendered ineffective by the reaction with the antibodies produced by the immune system. Secondly, repeated administration of non-human monoclonal antibodies may elicit such severe immune reactions that they will be detrimental to the patient. Methods for producing less antigenic antibody fragments and methods for humanizing antibodies have been proposed, but, if feasible at all, these methods are not very economical and will their own give rise to problems

regarding to half-life and bio-availability. Consequently, using anti-IL-6 monoclonal antibodies in the treatment of IL-6 related disease is considered not to be feasible.

[0008] Inhibitors or antagonists based upon mutagenesis of IL-6 have also been proposed, such as IL-6.Q160E/T163P (Brakenhoff, J., de Hon, F., Fontaine, V., et al.; J. Biol. Chem.; 269:86-93 (1994)), and IL-6.Q159E/T162P (Ehlers, M., de Hon, D., Klaasse Bos, H, et al., J. Biol. Chem.; 270:8158-8163 (1995)). It has been shown with these mutant proteins that receptor binding of IL-6 and signal transduction of IL-6 can be separated ~~in-vitro~~ *in vitro*. However, such mutant proteins are also foreign to the body of the patient to be treated and will also elicit an unwanted and unfavourable immune response that generally is detrimental to the treatment. Furthermore, such mutant proteins may only be partly effective, in that, although they may effectively block or inhibit specific IL-6 activities, at the same time they may exert other effects on the cytokine network with additional, still remaining, reactive sites present on these proteins. Therapeutic treatment with such reagents would then elicit other, yet unpredictable, side effects. A great disadvantage of earlier reported mutant IL-6 and IL-6 receptor antagonists is that these molecules, instead of inhibiting IL-6 ~~in-vitro~~ *in vitro*, act as carrier and increase the half-life time and result in an increase of IL-6 activity ~~in-vivo~~ *in vivo*. Moreover, these mutant IL-6 and IL-6 receptor antagonists have a low affinity to their target molecules and will likely act as an immunogen. In addition, antibodies raised to IL-6 stabilize IL-6 and result in an increased IL-6 production. Accumulation of circulating IL-6 as stable IL-6-anti-IL-6 complexes as a result of treatment with these antibodies to IL-6, will occur as no renal filtration can be expected. Repeated use of nonhumanized IL-6 antibodies to human patients will most likely induce antibody production to these antibodies, and result in formation of immune-complexes (Heremans, H., Dillen, C., et al. J. Immunol. 22;:2395-2401).

#### SUMMARY OF THE INVENTION

[0009] The present invention provides a solution to the above-illustrated problems without hampering the possibility of therapeutic treatment of IL-6 related disease. The above methods to inhibit IL-6 activity by antibodies or mutants, differ greatly from the invention as described here: peptides that antagonize or agonize IL-6 at the binding site to the receptor in three ways: at the IL-6 part, at the  $\alpha$ -receptor part, and at the gp130-receptor part. These

antagonists and agonists and combinations of these antagonists and/or agonists as multimeric peptides or as single peptides with defined pharmacokinetic characteristics gives a powerful tool to manage IL-6 bioactivity. With the solution provided by the present invention, immune responses to the treatment do not occur. Further, the occurrence of unpredictable side effects is greatly minimized.

**[0010]** The invention provides synthetic peptides that interact with the receptor site of IL-6 or with IL-6 receptors ( $\alpha$  and  $\beta$ ) present at target cells.

**[0011]** The invention further provides synthetic peptides that, when combined, interact with the receptor site of IL-6 as well as with IL-6 receptors ( $\alpha$  and  $\beta$ ) present at target cells. A mixture of these peptides is particularly valuable as the pharmacological properties of the peptides can be adjusted to obtain a maximal desired effect. Moreover, half-life time can be prolonged by inserting unnatural amino-acids into the synthetic peptides. The antagonizing or agonizing activity of the peptides is increased by producing di- or multi-meric peptides directed to one or more receptor sites. Such di- or multi-meric peptides can for instance be made by linking the peptides via one or more amino-acids such as lysine (Tam, PNAS 1988, 85: 5409-5413). The distribution of the peptides into target organs can be optimized by adjusting the hydrophilic or lipophylic nature of peptides or by binding of these peptides onto peptides that interact with specific organ markers. Finally, the peptides provided can be bound onto the solid phase of membranes or filters that are connected into an extra-corporal blood circulation circuit of the patient. A more efficient clearance of IL-6 and/or soluble IL-6 receptors can in that way be achieved.

**[0012]** Such synthetic peptides can be derived from (A) IL-6, or derived from (B) the receptor  $\alpha$ -chain of IL-6 (IL-6R $\alpha$ , CD126), or from (C) the receptor  $\beta$ -chain of IL-6 (IL-6R $\beta$ , GP130, CD130) and exhibit antagonistic and agonistic activity against the various components and steps of the IL-6 signaling cascade. The peptides were found by testing sets of overlapping amino acid sequences from the published human ILE (Hirano, T., Yasukawa, K., Harada, H., et al.; Nature 324, 73-76 (1986); Yasukawa, R., Hirano, T., Watanabe Y., et al.; EMBO J. 6:2939-2945 (1987), IL-6Ra (Yamasaki, K., Taga, T., Hirata, Y., et al.; Science 241:825-828 (1988)) and IL-6R $\beta$  (Hibi, M., Murakami, M., Saito, M.; Cell 63:1149-1157 (1990)). These

overlapping peptides, each twelve amino acids long, were tested in an assay for antagonistic or agonistic IL-6 activity.

**[0013]** The peptides provided by the invention all exhibit antagonistic or agonistic IL-6 activity against the IL-6 signaling cascade as measured in an IL-6 assay. The peptides of the present invention are too small to generate immune responses. Further, they are too short to contain additional reactive sites, so that the antagonistic and, in addition, the agonistic peptides can advantageously be used to treat patients to counteract and adjust elevated IL-6 levels. The amino acids in all antagonistic or agonistic peptides described below are identified by the one letter code, in which the N-terminal (head) amino acid is listed first (on the left) and the C-terminal (tail) amino acid is listed last (on the right).

**[0014]** A. The antagonistic peptides derived from IL-6 preferably comprise at least 5 consecutive amino acids selected from the following 3 regions that were identified as RYILDGISALRK (SEQ ID NO:1), STKVLIQFLQKKAKNL (SEQ ID NO:2), and I[-]LRSFKEFLQSSLRALRQM (SEQ ID NO:3).

**[0015]** B. The antagonistic peptides derived from the receptor  $\alpha$ -chain of IL-6 preferably comprise at least 5 consecutive amino acids selected from the following 3 regions that were identified as QLSCFRKSPLSNVVC (SEQ ID NO:4), PRSTPSLTTKAVLLVRKFQNS (SEQ ID NO:5), and MCVASSVGSKFSKTQTFQGC (SEQ ID NO:6). The agonistic peptides derived from the receptor  $\alpha$ -chain of IL-6 preferably comprise at least 5 consecutive amino acids selected from the following region that was identified as EWGPRSTPSLTTKAVLLVRKFQNSPAED (SEQ ID NO:11).

**[0016]** C. The antagonistic peptides derived from the receptor  $\beta$ -chain of IL-6 preferably comprise at least 5 consecutive amino acids selected from the following 4 regions that were identified as PEKPKNLSCIVNEGKKMRCE[-]JWDGGR (SEQ ID NO:7), NFTLKSEWATHKFADCKAKRDTPTS (SEQ ID NO:8), WVEAENALGKVTS DH (SEQ ID NO:9), and PVYKVKPNPPHNLSVIN (SEQ ID NO:10).

**[0017]** Relatively short peptides (as short as a string of 5 amino acids) that are selected from any of the above peptides, or peptides of no more than 30 amino acids long which show antagonistic or agonistic activity as measured in an IL-6 assay and have at least one string of at least 5 amino acids in common with the peptides from groups A, B or C, are also peptides

of the present invention. The peptides according to the invention can vary in length. Also, the peptides comprising a string of at least 5 amino acids which are in common with the peptides from groups A, B, and C can be modified by replacing one or a few amino acids in said string by other amino acids. Such amino acids can be selected from any of the naturally occurring amino acids, but also amino acids that normally do not occur in nature can be used as replacement amino acids. The choice of the replacing amino acid can, for example, be guided by comparing IL-6 or IL-6 receptor sequences from other species than humans or by selecting amino acids that lead not to extreme functional or conformational changes of the selected peptide, but also other selection methods can be used. More in particular, the present invention relates in a first aspect to a peptide containing at least 5 amino acids and at most 30 amino acids that exhibits antagonistic activity directed against IL-6 and/or against the  $\alpha$ -chain of the IL-6 receptor and/or against the  $\beta$ -chain of the IL-6 receptor.

[0018] Also, the present invention relates in another aspect to a peptide containing at least 5 amino acids and at most 30 amino acids that can exhibit antagonistic or agonistic IL-6 activity, depending on the concentration in which it is used. An example of such peptides are peptides selected with as basis with the amino acid sequence EWGPRSTPSLTTKAVLLVRKFQNSPAED (SEQ ID NO:11) as found in the  $\alpha$ -chain of the IL-6 receptor. Surprisingly, peptides selected on the basis of the aforementioned sequence expressed antagonistic IL-6 activity at high concentrations whereas at low concentrations a marked agonistic activity was found. Agonistic activity was observed in the in-vitro in vitro bioassay in a concentration range from 7.5 to 120  $\mu$ g/ml peptide. At a concentration of  $\geq 120$   $\mu$ g/ml these peptides had an antagonistic effect upon the biological activity of IL-6 in the bioassay. The agonistic peptides can be used in-vitro in vitro in concentrations that are relatively equivalent but not necessarily the same as when used in-vitro in vitro.

[0019] Furthermore, the invention provides combinations of peptides, either provided as a simple mixture of several, possibly modified, peptides selected from groups A, B or C, or, provided as, possibly modified, peptides selected from groups A, B, or C that are linked, with direct chemical bonds or using spacer molecules, head to tail, or head to head, or tail to tail, or via side chains of the amino acids present in the selected peptides.

[0020] Examples of such combinations of peptides are, for example, using the peptides SLTTKAV (SEQ ID NO:15) and ILRSFKEFLQSS (SEQ ID NO:16), or WVEAENALGKVTSDH (SEQ ID NO:17) and RYILD (SEQ ID NO:18), or KAVLLVRK (SEQ ID NO:19) and KAVLLVRK, but many other combinations of two or more peptides can be selected from the peptides listed in groups A, B or C. Such combinations of peptides, be it simple mixtures or bound peptides, can advantageously be used to counteract the events occurring in the IL-6 signaling cascade, such as disrupting the binding of IL-6 to the  $\alpha$ -chain by simultaneously competing at both the IL-6 and the  $\alpha$ -chain binding site, or simultaneously competing at the binding sites of the IL-6/ $\alpha$ -chain complex and the  $\beta$ -chain.

[0021] The peptides of the invention can suitably be used in a medicinal or pharmaceutical preparation for therapeutic or prophylactic purposes. Further, they can be used in protocols to remove circulating IL-6 from the blood of diseased patients via dialysis methods in which the peptides are bound to a solid phase. Passing blood or blood filtrates along the thus bound peptides will result in clearance of IL-6 that will bind to the peptide at the solid phase. Also the peptides according to the invention may be added to blood or blood filtrates and (ir) - reversibly bind to IL-6 or IL-6 receptor molecules and thus render these inactive before they re-enter the body. Also, the peptides can be used in diagnostic tests, i.e., in direct binding or competition based enzyme-linked immunosorbent assays to measure IL-6 levels.

#### DETAILED DESCRIPTION OF THE INVENTION

[0022] IL-6 agonistic peptides can completely or partially replace IL-6 that is added to cell-cultures, for example, IL-6 is used to grow or culture IL-6 dependant cells, like B-cell hybridomas to which IL-6, as growth factor, is often added, ~~but also~~ In addition, cell-cultures in general will benefit from the addition of agonistic IL-6 peptides. The IL-6 agonistic peptides administered to humans or animals can be used to enhance the immune response of an host exposed to a specific immunogenic substance. The IL-6 agonistic peptides can be administered to humans or animals to increase the responsiveness of the immune system of the host. A specific use is in pharmaceutical preparations for topical or intramammary application. When these agonistic peptides are combined with IL-6 antagonists, as described, excess of IL-6 can be inhibited without loss of basal IL-6 signal transduction.

[0023] Antibodies specifically directed against the peptides, and their corresponding anti-idiotypic antibodies, are part of the invention. Such antibodies can, for example, be administered to patients treated earlier with the peptides, to counteract the effect of the peptides on the patient. Such antibodies can be used in the above-described dialysis protocols and diagnostic tests.

[0024] Synthesis of the peptides may be accomplished according to the available methods in the art. The synthesis of the exemplified peptides was done according to Valerio et al. (Int. J. Peptide Res., 42:1-9 (1993) and/or Valerio et al. (Int. J. Peptide Res., 44:148-165 (1994)). Methods for large scale production of synthetic peptides and the purification thereof are well known in the art. The invention is illustrated in the following experimental part.

#### Brief Description of Figures:

[0025] Fig. 1 Amino acid sequences and sources of selected peptides (SEQ ID NOs:12-14, FIGs. 1A-1C, respectively);

[0026] Fig. 2 Screening of synthesized peptides, representing IL-6, in the B9 bio-assay;

[0027] Fig. 3 Screening of synthesized peptides, representing IL-6Ra, in the B9 bio-assay;

[0028] Fig. 4 Screening of synthesized peptides, representing gp130, in the B9 bio-assay; and

[0029] Fig. 5 Screening synthetic peptides showing a region with agonistic activity (dilution 1:50).

#### Experimental part

##### 1. Peptide synthesis. Peptide synthesis.

[0030] The peptides of the examples which were intended for identifying active centers in the IL-6 and IL-6 receptor molecules were synthesized using a method according to Valerio et al. (Int. J. Peptide Res., 42:1-9 (1993) and/or Valerio et al. (Int. J. Peptide Res., 44:148-165 (1994)). Multimeric peptides (four branched) were synthesized by the solid-phase method, and using of a dispersed system with branching oligolysines as a scaffolding for incorporation of the synthesized antagonistic peptides (Tam, J.P.; Proc. Natl. Acad. Sci. USA, 85:5409-5413 (1988).

2. Proliferation assay to determine antagonistic IL-6 activity. Proliferation assay to determine antagonistic IL-6 activity.

[0031] A set of overlapping peptides, each twelve amino acids long (each consecutive peptide shifts one amino acid, so consecutive peptides have 11 amino acids in common), derived from human IL-6 sequence (Hirano, T., Yasukawa, K., Harada, H., et al.; Nature 324, 73-76 (1986); Yasukawa, R., Hirano, T., Watanabe Y., et al., EMBO J. 6:2939-2945 (1987), were incubated with cells (B9) at 37°C. After one hour, recombinant human IL-6 (CLB, Amsterdam, The Netherlands) was added at 3 different concentrations (2.5 U/ml, 5 U/ml and 10 U/ml).

[0032] A set of overlapping peptides, each twelve amino acids long (each consecutive peptide shifts one amino acid, so consecutive peptides have 11 amino acids in common), derived from human IL6Ra (Yamasaki, K., Taga, T., Hirata, Y., et al.; Science 241:825-828 (1988)) or qpl30 (Hibi, M., Murakami, M., Saito, N.; Cell 63:1149-1157 (1990)), were incubated with 3 different concentrations IL-6 (2.5 U/ml, 5 U/ml, 10 U/ml) diluted in DMEM supplemented with HT for one hour at 37°C. Then the residual IL-6 activity was determined in a biological assay by measuring the IL-6 dependant proliferative growth of B9 mouse hybridoma cells (Helle, M., Boeije, L., Aarden, L.A.; Eur. J. Immunol. 18:1535-1540 (1988)). Briefly, B9 mouse hybridoma cells were collected during their logarithmic growth phase in IL-6 free media and suspended at a concentration of  $1 \times 10^5$  cells/ml in DMEM+HT medium containing 5% FCS. Fifty  $\mu$ l of each IL-6 dilution was combined with each of the synthesized peptides representing IL-6 sequences and incubated for 1 hour at 37°C. This mixture was added in duplicate to 50  $\mu$ l of the B9 cell suspension in flat-bottomed 96-well tissue culture plates (Greiner) and incubated at 37°C and 5% CO<sub>2</sub> for 72 h. IL-6 activity was assessed by using 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide (MTT, Sigma). After addition of 25  $\mu$ l of MTT (5mg/ml dissolved in PBS) to each well and further incubation at 37°C for 4 h, 100  $\mu$ l of lysis buffer (20% w/v SDS in 50% dimethyl formamide) was added. Thereafter, incubation was continued over night at 37°C and the next morning absorbance was read at 578 nm.

[0033] To determine the agonistic or antagonistic activity to IL-6 of the peptides synthesized from the sequences of the IL-6 receptor  $\alpha$  or  $\beta$ , various concentrations of each of these peptides was combined with 50  $\mu$ l of the B9 cell suspension ( $1 \times 10^5$  cells/ml in

DMEM+HT medium containing 5% FCS). This suspension was incubated for 1 hour at 37°C, and combined with each of the dilutions of IL-6 into flat-bottomed 96-well tissue culture plates (Greiner). Plates were incubated at 37°C for 72 h. IL-6 activity was assessed as described above.

[0034] Samples without ~~synthetized~~ synthetic peptides or with a sham peptide but with IL-6 were used as positive control, whereas samples that contained neither IL-6 nor ~~synthetized~~ synthetic peptides were used as negative control. Inhibition or enhancement of IL-6 activity was determined by calculating the ratio absorbance of test sample and absorbance positive control both corrected for negative control ~~absorbance~~ absorbance.

### 3. Toxicity testing of peptides: Toxicity testing of peptides.

[0035] Three separate tests were performed to determine whether the ~~synthetized~~ synthetic peptides exert toxic effects in vitro upon erythrocytes (A), or polymorphonuclear cells (B), or hepatocytes (C).

[0036] A. Sheep red blood cells (SRBC) were washed five times in PBS. A 1% (v/v) suspension of erythrocytes was prepared in veronal-buffered saline that contained gelatin (GVS: 0.032% gelatin in 3.9 mM barbitone sodium, 1 mM MgSO<sub>4</sub>, 0.38 mM CaCl<sub>2</sub>, and 145.6 mM NaCl). Twofold dilutions of the synthetized peptides (50 µl) were made in U-shaped microtiter plates (Greiner Labortechnik) and 50 µl of the SRBC suspension were added to each well. Plates were sealed, mixed and incubated for 2 hours at 37°C. Thereafter, plates were examined for hemolysis. None of the synthetized peptides showed hemolysis.

[0037] B. Porcine polymorphonuclear cells (PMN) were isolated from pig blood (Cruisjen, T.L.M., Van Leengoed, L.A.M.G. et al.; Infect. Immun. 60:4867-4871 (1992)). Twofold dilutions of the ~~synthetized~~ synthetic peptides (50 µl) were made in flat-bottomed microtiter plates (Greiner Labortechnik) and 50 µl of the PMN suspension ( $2 \times 10^6$  cells/ml) were added to each well. Plates were sealed, gently mixed and incubated for 6 hours at 37°C and 5% CO<sub>2</sub>. Thereafter, plates were examined for cytotoxicity by nigrosine dye exclusion. None of the ~~synthetized~~ synthetic peptides was were toxic for PMN.

[0038] C. Porcine hepatocytes were isolated from liver of pigs based on Seglens' method (Seglen, P.O.; Methods Cell Biol 13:29-83 (1976)) and adapted according to

Monshouwer M., et al. (Toxicol. Applied Pharmacol. in press). Hepatocytes were suspended in Williams' medium E to a concentration of  $10^6$  cells/ml. From this suspension 1.5 ml was put into each well of 12-well tissue culture plates (Costar) and incubated for 12 h at 37°C. Adherent hepatocytes were examined for their viability and non-adherent hepatocytes were discarded. Each ~~synthetized~~ synthetic peptide was mixed with Williams' medium E (at dilutions of 1:50 and 1:100) and added to wells with adherent hepatocytes. After another 24 h incubation at 37°C viability was assessed by using 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma). After addition of 1.5 of MTT (1-mg/ml dissolved in Williams' medium E) to each well and further incubation at 37°C for 30 min, 1 ml of lysis buffer (0.8 M HCL in isopropanol) was added. Thereafter, plates were mixed for 10 min and absorbance was read at 560 nm. None of the synthetized peptides proved to affect the viability of the hepatocytes.

4. ~~Effect of IL-6 antagonistic peptides upon IL-6 induced acute phase reaction and downregulation of hepatic biotransformation activities.~~ Effect of IL-6 antagonistic peptides upon IL-6 induced acute phase reaction and down regulation of hepatic biotransformation activities.

[0039] Porcine hepatocytes were isolated from liver of pigs based on Seglens' method (Seglen, P.O.; Methods Cell Biol 13:29-83 (1976)) and adapted according to Monshouwer M., et al. (Toxicol. Applied Pharmacol. in press). Hepatocytes were suspended in Williams' medium E to a concentration of  $10^6$  cells/ml. From this suspension 1 ml was put into each well of 12-well tissue culture plates (Costar) and incubated for 12 h at 37°C. Adherent hepatocytes were examined for their viability and nonadherent hepatocytes were discarded. Each ~~synthetized~~ synthetic peptide was mixed (at dilutions of 1:50 and 1:100) with Williams' medium E containing IL-6 (1000 U/ml) and added to wells with adherent hepatocytes. Also a negative (containing no IL-6 and without synthetized peptides in the medium) and positive control (containing 1000 U/ml IL-6 in the medium) were prepared and tested. After an incubation period of 24 hours, the medium was removed and for each well CYP450 dependent enzyme activity of intact monolayers of hepatocytes was determined.

[0040] CYP450 enzyme assay. CYP450 dependent enzyme activity, using testosterone (250/ $\mu$ M) as substrate, was determined as previously described by Van 't Klooster et al. (Bioch. Pharmacol. 46;1781-1790 (1993)). Briefly, testosterone was mixed with Williams'

medium E without fetal calf serum and added to the wells with hepatocytes. After 30 min incubation at 37°C and 5% CO<sub>2</sub>, hydroxylated testosterone metabolites in the medium were quantified by HPLC.

[0041] HPLC analysis. Aliquots of 1 ml of medium was mixed with 100 µl of a solution of 11β-testosterone (12,5 µg/ml) in methanol as internal standard and extracted with 5 ml dichlormethane. The organic phase was transferred to clean tubes and evaporated to dryness at room temperature under a stream of nitrogen. The residues were dissolved in 130 µl 50% methanol and 20 µl of these solutions were injected for HPLC analysis. The stationary phase consisted of a C18 glass\_column (20 cm, 3µm particle size, Chrompack, Middelburg, the Netherlands). The mobile phase consisted of buffer A (12% methanol, 75% milli Q water) and buffer B (64% methanol, 6% acetonitril, 30% milli Q water). With these buffers, an elution gradient was generated; 10-58% B from 0-45 minutes; 58-59% from 45-50 minutes; 59-10% from 50-53 minutes, with a flow rate of 0,8 ml/min. Metabolites were detected ~~spectrofotometrically~~ spectrophotometrically at 254 nm. Inhibition of IL-6 dependant downregulation of cytochrome P450 was determined by comparing the relative concentration of hydroxylated testosterone metabolites in medium from adherent hepatocytes incubated with synthesized peptides and IL-6, and the relative concentration of hydroxylated testosterone metabolites in medium from positive and negative control hepatocyte monolayers.

## 5. Results.

[0042] Peptides derived from hIL-6, hgp130 (the α-chain of the IL-6 receptor) and hIL6Ra (the α-chain of the IL-6 receptor) were ~~analysed~~ analyzed for antagonistic IL-6 activity.

[0043] For hIL-6 peptides, 3 regions were identified which inhibited IL-6 activity in an IL-6 assay (~~fig~~ FIG. 2). Peptide 31, 119-123 and 167-174 represent the identified regions (RYILDGISALRK (SEQ ID NO:1), resp. STKVLIQFLQKKAKNL (SEQ ID NO:2), resp. ILRSFKEFLQSSLRALRQM (SEQ ID NO:3)).

[0044] For hILGRa, also 3 regions were identified which inhibited IL-6 activity in an IL-6 assay (~~fig~~ FIG. 3). Peptide 6-9, 24-33 and 80-89 represent the identified regions (QLSCFRKSPLSNVVC (SEQ ID NO:4), resp. PRSTPSLTTKAVLLVRKFQNS (SEQ ID NO:5), resp. MCVASSVGSKFSKTQTFQGC (SEQ ID NO:6)).

**[0045]** For hgpl30 peptides, 4 regions were identified which inhibited IL-6 activity in an IL-6 assay (fig FIG. 4). Peptide 2-15, 33-46, 73-76 and 92-97 represent the identified regions (PEKPKNLSCIVNEGKKMRCEWDGGR (SEQ ID NO:7), resp. NFTLKSE[-]WATHKFADCKAKRDTPTS (SEQ ID NO:8), resp. WVEAENALGKVTSDH (SEQ ID NO:19), resp. PVYKVKPNPPHNLVIN (SEQ ID NO:10)).

**[0046]** The identified peptides with anti-IL-6 activity were not lytic for erythrocytes and not toxic for polymorpho-nuclear cells and not toxic for primary hepatocyte culture cells.

**[0047]** Peptides derived from hIL6Ra (the  $\alpha$ -chain of the IL-6 receptor) were analysed for agonistic IL-6 activity and 1 region was identified which stimulated proliferation of B9 cells without IL-6 added to the medium and enhanced IL-6 activity in the B9 bio-assay (fig. FIG. 5). Peptide 21-37 represent the region EWGPRSTPSLTTKAVLLVRKFQNSPAED (SEQ ID NO:11) of the IL-6Ra sequence

**[0048]** Agonistic activity was observed in a concentration range from 7.5 to 120  $\mu$ g/ml peptide. These peptides induced ~~prolife-rative~~ proliferative growth of the IL-6 dependant cell line B9, and when combined with IL-6 enhanced proliferation of the B9 cell line was examined and thus the biological activity of IL-6 was enhanced. At a concentration of  $\geq 120$   $\mu$ g/ml these agonistic peptides had an antagonistic effect upon the biological activity of IL-6.

**[0049]** The identified peptides with agonistic IL-6 activity were not lytic for erythrocytes and not toxic for polymorphonuclear cells and not toxic for primary hepatocyte culture cells.

**[0050]** ~~Synthesized~~ Synthesized peptides from the regions PVYKVKPNPPHNLVIN (SEQ ID NO:10), WVEAENALGKVTSDH (SEQ ID NO:9), and MCVASSVGSKFSKTQTFQGC (SEQ ID NO:6) inhibit IL-6 regulated down-regulation of cytochrome P-450 of hepatocytes.

## ABSTRACT

The invention relates to IL-6 and IL-6 receptor derived peptides having IL-6 agonistic or antagonistic activity. The peptides are at least 5 amino acids long and are selected from one of the following amino acid sequences: RYILDGISALRK (SEQ ID NO: 1); STKVLIQFLQKKAKNL (SEQ ID NO: 2); ILRSFKEFLQSSLRALRQM (SEQ ID NO: 3); QLSCFRKSPLSNVVC (SEQ ID NO: 4); PRSTPSLTTKAVLLLVRKFQNS (SEQ ID NO: 5); MCVASSVGSKFSKTQTFQGC (SEQ ID NO: 6); PEKPKNLSCIVNEGKKMRCEWDGGR (SEQ ID NO: 7); NFTLKSEQATHKFADCKAKRDTPTS (SEQ ID NO: 8); WVEAENALGKVTS DH (SEQ ID NO: 9); EWGPRSTPSLTTKAVLLLVRKFQNSPAED (SEQ ID NO: 11); or PVYKVKPNPPHNLSVIN (SEQ ID NO: 10). Selected peptides and combinations of selected peptides can be used in the treatment, prevention, detection, or diagnosis of IL-6 related disease and can be used to clear blood or blood products of IL-6 or IL-6 receptor molecules.

SEQUENCE LISTING

~~<110> van Leengoed, Leonardus Adrianus Maria Govardus~~

~~—— Hoebe, Kasper Hubertus Nicolaas~~

~~—— Meleen, Robert Hans~~

~~<120> IL-6 and IL-6 receptor derived peptide having IL-6 antagonistic or agonistic activity~~

~~<130> 2183-3890US~~

~~<140> US 09/202,104~~

~~<141> 1999-04-30~~

~~<150> EP 96201720.8~~

~~<151> 1996-06-20~~

~~<150> PCT/NL97/00345~~

~~<151> 1997-06-19~~

~~<160> 19~~

~~<170> Patent in version 3.0~~

~~<210> 1~~

~~<211> 12~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region in IL-6~~

~~<400> 1~~

~~Arg Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Leu~~

~~1 5 10~~

~~<210> 2~~

~~<211> 16~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region in IL-6~~

~~<400> 2~~

Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn Leu  
1 5 10 15

~~<210> 3~~

~~<211> 19~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region in IL-6~~

~~<400> 3~~

~~Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg Ala Leu~~  
1 ————— 5 ————— 10 ————— 15

~~Arg Gln Met~~

~~<210> 4~~

~~<211> 15~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region of receptor alpha-chain of IL-6~~

~~<400> 4~~

~~Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser Asn Val Val Cys~~  
1 ————— 5 ————— 10 ————— 15

~~<210> 5~~

~~<211> 21~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region of receptor alpha-chain of IL-6~~

~~<400> 5~~

~~Pro Arg Ser Thr Pro Ser Leu Thr Thr Lys Ala Val Leu Leu Val Arg~~  
~~1 5 10 15~~

~~Lys Phe Gln Asn Ser~~  
~~20~~

~~<210> 6~~

~~<211> 20~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region of receptor alpha chain of IL-6~~

~~<400> 6~~

~~Met Cys Val Ala Ser Ser Val Gly Ser Lys Phe Ser Lys Thr Cln Thr~~  
1 5 10 15

~~Phe Cln Gly Cys~~  
20

~~<210> 7~~

~~<211> 25~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region of receptor beta chain of IL-6~~

~~<400> 7~~

~~Pro Glu Lys Pro Lys Asn Leu Ser Cys Ile Val Asn Glu Gly Lys Lys~~  
1 5 10 15

~~Met Arg Cys Glu Trp Asp Gly Gly Arg~~  
\_\_\_\_\_20\_\_\_\_\_25

<210>—8

<211>—25

<212>—PRT

<213>—Artificial Sequence

<220>

<221>—misc\_feature

<223>—Description of Artificial Sequence: region of receptor beta-chain  
\_\_\_\_\_of IL-6

<400>—8

~~Asn Phe Thr Leu Lys Ser Glu Trp Ala Thr His Lys Phe Ala Asp Cys~~  
1\_\_\_\_\_5\_\_\_\_\_10\_\_\_\_\_15

~~Lys Ala Lys Arg Asp Thr Pro Thr Ser~~  
\_\_\_\_\_20\_\_\_\_\_25

<210>—9

<211>—15

<212>—PRT

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region of receptor beta-chain  
of IL-6~~

~~<400> 9~~

~~Trp Val Glu Ala Glu Asn Ala Leu Gly Lys Val Thr Ser Asp His  
1 5 10 15~~

~~<210> 10~~

~~<211> 17~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region of receptor beta-chain  
of IL-6~~

~~<400> 10~~

~~Pro Val Tyr Lys Val Lys Pro Asn Pro Pro His Asn Leu Ser Val Ile~~  
1 5 10 15

~~Asn~~

~~<210> 11~~

~~<211> 28~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region of receptor alpha chain of IL-6~~

~~<400> 11~~

~~Glu Trp Gly Pro Arg Ser Thr Pro Ser Leu Thr Thr Lys Ala Val Leu~~  
1 5 10 15

~~Leu Val Arg Lys Phe Gln Asn Ser Pro Ala Glu Asp~~  
20 25

~~<210> 12~~

~~<211> 187~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: human IL-6 peptide~~

~~<400> 12~~

~~Ala Pro Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro~~  
~~1 5 10 15~~

~~His Arg Gln Pro Leu Thr Ser Ser Glu Arg Ile Ser Lys Gln Ile Arg~~  
~~20 25 30~~

~~Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys Glu Thr Cys Asn Lys~~  
~~35 40 45~~

~~Ser Asn Met Cys Glu Ser Ser Lys Glu Ala Leu Ala Glu Asn Asn Leu~~  
~~50 55 60~~

~~Asn Leu Pro Lys Met Ala Glu Lys Asp Gly Cys Phe Gln Ser Gly Phe~~  
~~65 70 75 80~~

~~Asn Glu Glu Thr Cys Leu Val Lys Ile Ile Thr Gly Leu Leu Glu Phe~~  
~~85 90 95~~

~~Glu Val Tyr Leu Glu Tyr Leu Gln Asn Arg Phe Glu Ser Ser Glu Glu~~

~~100 105 110~~  
~~Gln Ala Arg Ala Val Gln Met Ser Thr Lys Val Leu Ile Gln Phe Leu~~  
~~115 120 125~~  
~~Gln Lys Lys Ala Lys Asn Leu Asp Ala Ile Thr Thr Pro Asp Pro Thr~~  
~~130 135 140~~  
~~Thr Asn Ala Ser Leu Leu Thr Lys Leu Gln Ala Gln Asn Gln Trp Leu~~  
~~145 150 155 160~~  
~~Gln Asp Met Thr Thr His Leu Ile Leu Ile Arg Ser Phe Lys Glu Phe~~  
~~165 170 175~~  
~~Leu Gln Ser Ser Leu Arg Ala Leu Arg Gln Met~~  
~~180 185~~

~~<210> 13~~

~~<211> 112~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: receptor alpha-chain of IL-6~~

<220>

<221> Xaa

<222> (60)..(65)

<223> Xaa on pos. 60 and 65 is unknown

<400> 13

Pro Pro Glu Glu Pro Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser  
1 5 10 15

Asn Val Val Cys Glu Trp Gly Pro Arg Ser Thr Pro Ser Leu Thr Thr  
20 25 30

Lys Ala Val Leu Leu Val Arg Lys Phe Gln Asn Ser Pro Ala Glu Asp  
35 40 45

Phe Gln Glu Pro Cys Gln Tyr Ser Gln Glu Ser Xaa Lys Phe Ser Cys  
50 55 60

Xaa Leu Ala Val Pro Glu Gly Asp Ser Ser Phe Tyr Ile Val Ser Met  
65 70 75 80

Cys Val Ala Ser Ser Val Gly Ser Lys Phe Ser Lys Thr Gln Thr Phe  
85 90 95

Gln Gly Cys Gly Ile Leu Gln Pro Asp Pro Pro Ala Asn Ile Thr Val  
100 105 110

<210> 14

<211> 108

<212> ~~PRT~~

<213> ~~Artificial Sequence~~

<220>

<221> ~~misc\_feature~~

<223> ~~Description of Artificial Sequence: receptor beta-chain of IL-6~~

<400> 14

~~Pro Pro Glu Lys Pro Lys Asn Leu Ser Cys Ile Val Asn Glu Gly Lys~~  
1 ————— 5 ————— 10 ————— 15

~~Lys Met Arg Cys Glu Trp Asp Gly Gly Arg Glu Thr His Leu Glu Thr~~  
————— 20 ————— 25 ————— 30

~~Asn Phe Thr Leu Lys Ser Glu Trp Ala Thr His Lys Phe Ala Asp Cys~~  
————— 35 ————— 40 ————— 45

~~Lys Ala Lys Arg Asp Thr Pro Thr Ser Cys Thr Val Asp Tyr Ser Thr~~  
—— 50 ————— 55 ————— 60

~~Val Tyr Phe Val Asn Ile Glu Val Trp Val Glu Ala Glu Asn Ala Leu~~  
65 ————— 70 ————— 75 ————— 80

~~Gly Lys Val Thr Ser Asp His Ile Asn Phe Asp Pro Val Tyr Lys Val~~  
————— 85 ————— 90 ————— 95

~~Lys Pro Asn Pro Pro His Asn Leu Ser Val Ile Asn~~  
————— 100 ————— 105

~~<210> 15~~

~~<211> 7~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region in IL-6~~

~~<400> 15~~

~~Ser Leu Thr Thr Lys Ala Val~~  
~~1 5~~

~~<210> 16~~

~~<211> 12~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region in IL-6~~

~~<400> 16~~

~~Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser~~  
1 ————— 5 ————— 10

~~<210> 17~~

~~<211> 15~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region in IL-6~~

~~<400> 17~~

~~Trp Val Glu Ala Glu Asn Ala Leu Gly Lys Val Thr Ser Asp His~~  
1 ————— 5 ————— 10 ————— 15

~~<210> 18~~

~~<211> 5~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region in IL-6~~

~~<400> 18~~

~~Arg Tyr Ile Leu Asp~~

~~1—————5~~

~~<210> 19~~

~~<211> 8~~

~~<212> PRT~~

~~<213> Artificial Sequence~~

~~<220>~~

~~<221> misc\_feature~~

~~<223> Description of Artificial Sequence: region in IL-6~~

<400> 19

Lys-Ala-Val-Leu-Leu-Val-Arg-Lys

1-----5

<110> van Leengoed, Leonardus Adrianus Maria Govardus

Hoebe, Kasper Hubertus Nicolaas

Meloen, Robert Hans

<120> IL-6 and IL-6 receptor derived peptide having IL-6 antagonistic  
or agonistic activity

<130> 2183-3890US

<140> US 09/202,104

<141> 1999-04-30

<150> EP 96201720.8

<151> 1996-06-20

<150> PCT/NL97/00345

<151> 1997-06-19

<160> 19

<170> PatentIn version 3.2

<210> 1

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> region in IL-6

<400> 1

Arg Tyr Ile Leu Asp Gly Ile Ser Ala Leu Arg Lys

1 5 10

<210> 2

<211> 16

<212> PRT

<213> Artificial Sequence

<220>

<223> region in IL-6

<400> 2

Ser Thr Lys Val Leu Ile Gln Phe Leu Gln Lys Lys Ala Lys Asn Leu

1 5 10 15

<210> 3

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> region in IL-6

<400> 3

Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser Leu Arg Ala Leu

1 5 10 15

Arg Gln Met

<210> 4

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> region of receptor alpha-chain of IL-6

<400> 4

Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser Asn Val Val Cys

1 5 10 15

<210> 5

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> region of receptor alpha-chain of IL-6

<400> 5

Pro Arg Ser Thr Pro Ser Leu Thr Thr Lys Ala Val Leu Leu Val Arg

1 5 10 15

Lys Phe Gln Asn Ser

20

<210> 6

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> region of receptor alpha-chain of IL-6

<400> 6

Met Cys Val Ala Ser Ser Val Gly Ser Lys Phe Ser Lys Thr Gln Thr

1 5 10 15

Phe Gln Gly Cys

20

<210> 7

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> region of receptor beta-chain of IL-6

<400> 7

Pro Glu Lys Pro Lys Asn Leu Ser Cys Ile Val Asn Glu Gly Lys Lys

1 5 10 15

Met Arg Cys Glu Trp Asp Gly Gly Arg

20 25

<210> 8

<211> 25

<212> PRT

<213> Artificial Sequence

<220>

<223> region of receptor beta-chain of IL-6

<400> 8

Asn Phe Thr Leu Lys Ser Glu Trp Ala Thr His Lys Phe Ala Asp Cys

1 5 10 15

Lys Ala Lys Arg Asp Thr Pro Thr Ser

20 25

<210> 9

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> region of receptor beta-chain of IL-6

<400> 9

Trp Val Glu Ala Glu Asn Ala Leu Gly Lys Val Thr Ser Asp His

1 5 10 15

<210> 10

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> region of receptor beta-chain of IL-6

<400> 10

Pro Val Tyr Lys Val Lys Pro Asn Pro Pro His Asn Leu Ser Val Ile

1 5 10 15

Asn

<210> 11

<211> 28

<212> PRT

<213> Artificial Sequence

<220>

<223> region of receptor alpha-chain of IL-6

<400> 11

Glu Trp Gly Pro Arg Ser Thr Pro Ser Leu Thr Thr Lys Ala Val Leu

1 5 10 15

Leu Val Arg Lys Phe Gln Asn Ser Pro Ala Glu Asp

20 25

<210> 12

<211> 187

<212> PRT

<213> Artificial Sequence

<220>

<223> human IL-6 peptide

<400> 12

Ala Pro Pro Val Pro Pro Gly Glu Asp Ser Lys Asp Val Ala Ala Pro

1 5 10 15

His	Arg	Gln	Pro	Leu	Thr	Ser	Ser	Glu	Arg	Ile	Ser	Lys	Gln	Ile	Arg		
					20						25						30

Tyr	Ile	Leu	Asp	Gly	Ile	Ser	Ala	Leu	Arg	Lys	Glu	Thr	Cys	Asn	Lys		
					35						40						45

Ser	Asn	Met	Cys	Glu	Ser	Ser	Lys	Glu	Ala	Leu	Ala	Glu	Asn	Asn	Leu		
					50						55						60

Asn	Leu	Pro	Lys	Met	Ala	Glu	Lys	Asp	Gly	Cys	Phe	Gln	Ser	Gly	Phe			
65						70						75						80

Asn	Glu	Glu	Thr	Cys	Leu	Val	Lys	Ile	Ile	Thr	Gly	Leu	Leu	Glu	Phe		
					85						90						95

Glu	Val	Tyr	Leu	Glu	Tyr	Leu	Gln	Asn	Arg	Phe	Glu	Ser	Ser	Glu	Glu		
					100						105						110

Gln	Ala	Arg	Ala	Val	Gln	Met	Ser	Thr	Lys	Val	Leu	Ile	Gln	Phe	Leu		
					115						120						125

Gln	Lys	Lys	Ala	Lys	Asn	Leu	Asp	Ala	Ile	Thr	Thr	Pro	Asp	Pro	Thr		
					130						135						140

Thr	Asn	Ala	Ser	Leu	Leu	Thr	Lys	Leu	Gln	Ala	Gln	Asn	Gln	Trp	Leu			
145						150						155						160

Gln Asp Met Thr Thr His Leu Ile Leu Ile Arg Ser Phe Lys Glu Phe  
165 170 175

Leu Gln Ser Ser Leu Arg Ala Leu Arg Gln Met  
180 185

<210> 13

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> receptor alpha-chain of IL-6

<220>

<221> Xaa

<222> (60)..(65)

<223> Xaa on pos. 60 and 65 is unknown

<220>

<221> misc feature

<222> (60)..(60)

<223> Xaa can be any naturally occurring amino acid

<220>

<221> misc feature

<222> (65)..(65)

<223> Xaa can be any naturally occurring amino acid

<400> 13

Pro Pro Glu Glu Pro Gln Leu Ser Cys Phe Arg Lys Ser Pro Leu Ser  
1 5 10 15

Asn	Val	Val	Cys	Glu	Trp	Gly	Pro	Arg	Ser	Thr	Pro	Ser	Leu	Thr	Thr
20					25					30					

Lys	Ala	Val	Leu	Leu	Val	Arg	Lys	Phe	Gln	Asn	Ser	Pro	Ala	Glu	Asp
35					40					45					

Phe	Gln	Glu	Pro	Cys	Gln	Tyr	Ser	Gln	Glu	Ser	Xaa	Lys	Phe	Ser	Cys
50					55					60					

Xaa	Leu	Ala	Val	Pro	Glu	Gly	Asp	Ser	Ser	Phe	Tyr	Ile	Val	Ser	Met
65			70					75					80		

Cys	Val	Ala	Ser	Ser	Val	Gly	Ser	Lys	Phe	Ser	Lys	Thr	Gln	Thr	Phe
85					90					95					

Gln	Gly	Cys	Gly	Ile	Leu	Gln	Pro	Asp	Pro	Pro	Ala	Asn	Ile	Thr	Val
100					105					110					

<210> 14

<211> 108

<212> PRT

<213> Artificial Sequence

<220>

<223> eceptor beta-chain of IL-6

<400> 14

Pro	Pro	Glu	Lys	Pro	Lys	Asn	Leu	Ser	Cys	Ile	Val	Asn	Glu	Gly	Lys
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

1                      5                      10                      15

Lys Met Arg Cys Glu Trp Asp Gly Gly Arg Glu Thr His Leu Glu Thr  
                    20                      25                      30

Asn Phe Thr Leu Lys Ser Glu Trp Ala Thr His Lys Phe Ala Asp Cys  
                    35                      40                      45

Lys Ala Lys Arg Asp Thr Pro Thr Ser Cys Thr Val Asp Tyr Ser Thr  
                    50                      55                      60

Val Tyr Phe Val Asn Ile Glu Val Trp Val Glu Ala Glu Asn Ala Leu  
65                      70                      75                      80

Gly Lys Val Thr Ser Asp His Ile Asn Phe Asp Pro Val Tyr Lys Val  
                    85                      90                      95

Lys Pro Asn Pro Pro His Asn Leu Ser Val Ile Asn  
                    100                      105

<210> 15

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> region in IL-6

<400> 15

Ser Leu Thr Thr Lys Ala Val

1 5

<210> 16

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> region in IL-6

<400> 16

Ile Leu Arg Ser Phe Lys Glu Phe Leu Gln Ser Ser

1 5 10

<210> 17

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> region in IL-6

<400> 17

Trp Val Glu Ala Glu Asn Ala Leu Gly Lys Val Thr Ser Asp His

1 5 10 15

<210> 18

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> region in IL-6

<400> 18

Arg Tyr Ile Leu Asp

1 5

<210> 19

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> region in IL-6

<400> 19

Lys Ala Val Leu Leu Val Arg Lys

1 5